Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號 規(guī)格
Recombinant Human Glycodelin (PAEP) CSB-EP017381HU 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Human Glycodelin (PAEP) CSB-MP017381HU 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Human Phenylalanine-4-hydroxylase (PAH) CSB-EP017396HU 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Rat Carboxypeptidase A1 (Cpa1) CSB-EP005875RA 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Human Myc proto-oncogene protein (MYC) CSB-EP015270HU 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Mouse Immunoglobulin J chain (Jchain) CSB-EP011337MO 1mg(1mg*1 or 500ug*2)/100μg/20μg
Recombinant Human Band 3 anion transport protein (SLC4A1),Partial CSB-EP021663HU 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Bovine Guanine nucleotide-binding protein G (t) subunit alpha-2 (GNAT2) CSB-EP009599BO 1mg(1mg*1 or 500ug*2)/100μg/20μg
Recombinant Human Interferon alpha-6 (IFNA6) CSB-EP011042HU 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Human Plasminogen activator inhibitor 2 (SERPINB2) CSB-MP021070HU 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Human Lupus La protein (SSB) CSB-EP022705HU 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Dog Inactive pancreatic lipase-related protein 1 (PNLIPRP1) CSB-EP018263DO 1mg(1mg*1 or 500ug*2)/100μg/20μg
Recombinant Human Neurofilament light polypeptide (NEFL) CSB-EP015688HU 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Mouse Collagen alpha-2 (IV) chain (Col4a2), partial CSB-EP005742MO 1mg(1mg*1 or 500ug*2)/100μg/20μg
Recombinant Human CD63 antigen (CD63), partial CSB-EP004950HU1 1mg(1mg*1 or 500ug*2)/100μg/20μg
Recombinant Human Fructose-1,6-bisphosphatase 1 (FBP1) CSB-EP008459HU 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Human Annexin A4 (ANXA4) CSB-EP001845HU 1mg(1mg*1 or 500ug*2)/100μg/20μg
Recombinant Mouse Cytotoxic T-lymphocyte protein 4 (Ctla4),Partial CSB-EP006163MO1 1mg(1mg*1 or 500ug*2)/100μg/20μg
Recombinant Human Interleukin-1 beta (IL1B) CSB-EP011614HU 1mg(1mg*1 or 500ug*2)/100ug/20ug
Recombinant Human Vitamin D-binding protein (GC), partial CSB-EP009306HU 1mg(1mg*1 or 500ug*2)/100ug/20ug

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達載體的選擇、表達蛋白的長度(全長或部分)、是否帶標簽等。在生產(chǎn)重組蛋白時,你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實驗更有可能成功。但是如果你做了錯誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗總結(jié)出了幾個有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達載體?

表達載體是一種DNA分子,它攜帶特定的基因進入宿主細胞,并利用細胞的蛋白質(zhì)合成機制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達載體可使外源基因在宿主細胞中高效表達,經(jīng)過多年的發(fā)展,表達載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標題所示,本文主要總結(jié)了幾個有用的技巧來選擇合適的表達載體。

第三條:如何表達具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應用,對其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達服務,您可以點擊這里獲取更多信息。注:如果您對CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價格、交貨、質(zhì)量等,您可以點擊橙色按鈕為我們在線留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>